INT121087

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2004
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 2.69
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Pde7a)
Anatomy Link Frequency
neuronal 1
vasculature 1
lung 1
Pde7a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 13 99.68 Very High Very High Very High
potassium channel 2 92.40 High High
tetrodotoxin 2 75.28 Quite High
Neurotransmitter 2 56.24 Quite High
Neuronal nitric oxide synthase 1 37.92 Quite Low
cva 3 24.40 Low Low
tolerance 6 5.00 Very Low Very Low Very Low
fibrosis 5 5.00 Very Low Very Low Very Low
nud 4 5.00 Very Low Very Low Very Low
Calcium channel 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Erectile Dysfunction 125 99.76 Very High Very High Very High
Pulmonary Hypertension 177 95.56 Very High Very High Very High
Increased Venous Pressure Under Development 24 95.04 Very High Very High Very High
Reprotox - General 2 47 91.72 High High
Disease 33 91.56 High High
Female Sexual Arousal Disorder 1 82.40 Quite High
Urological Neuroanatomy 1 65.12 Quite High
Syncope 3 56.80 Quite High
Pressure And Volume Under Development 6 56.28 Quite High
Hypertension 9 41.84 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Phosphodiesterase type 5 is highly expressed in lung tissues and is the principal phosphodiesterase isoform responsible for hydrolysis of cyclic GMP (Corbin et al. 2005).
Gene_expression (expressed) of Phosphodiesterase type 5 in lung
1) Confidence 0.17 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.40 Pain Relevance 0
Since phosphodiesterase type 5 is highly expressed in lung vasculature, tadalafil may also offer therapeutic benefit as a pulmonary vasodilator in patients with pulmonary arterial hypertension (PAH) (Corbin et al. 2005; Hemnes & Champion 2006; Raja et al. 2006; Sastry 2006).
Gene_expression (expressed) of phosphodiesterase type 5 in vasculature associated with pulmonary hypertension
2) Confidence 0.17 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.55 Pain Relevance 0
Since phosphodiesterase type 5 is highly expressed in pulmonary vascular tissues, agents that selectively inhibit phosphodiesterase type 5 activity induce pulmonary arterial vasodilatation, and are being developed for the treatment of PAH.


Gene_expression (expressed) of phosphodiesterase type 5 associated with pulmonary hypertension and increased venous pressure under development
3) Confidence 0.13 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.83 Pain Relevance 0.05
Rat clitorises express components of the proposed pathway: neuronal and endothelial NO synthases, soluble guanylyl cyclase (sGC), type 5 phosphodiesterase (PDE-5), and BK(Ca) channels.
Gene_expression (express) of type 5 phosphodiesterase in neuronal
4) Confidence 0.04 Published 2004 Journal FASEB J. Section Abstract Doc Link 15333581 Disease Relevance 0.17 Pain Relevance 0.23
The physiology of erection and the role of phosphodiesterase type 5
Gene_expression (role) of phosphodiesterase type 5
5) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643112 Disease Relevance 0.74 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox